Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Population pharmacokinetic-pharmacodynamic target attainment analysis of imipenem plasma and urine data in neonates and children.

Yoshizawa K, Ikawa K, Ikeda K, Ohge H, Morikawa N.

Pediatr Infect Dis J. 2013 Nov;32(11):1208-16. doi: 10.1097/INF.0b013e31829b5880.

PMID:
23676856
2.

Optimisation of imipenem regimens in patients with impaired renal function by pharmacokinetic-pharmacodynamic target attainment analysis of plasma and urinary concentration data.

Yoshizawa K, Ikawa K, Ikeda K, Kumon H, Ohge H, Morikawa N.

Int J Antimicrob Agents. 2012 Nov;40(5):427-33. doi: 10.1016/j.ijantimicag.2012.06.011.

PMID:
22877766
3.

Pharmacokinetic–pharmacodynamic target attainment analysis of meropenem in Japanese adult patients.

Ikawa K, Morikawa N, Ohge H, Ikeda K, Sueda T, Taniwaki M, Kurisu K.

J Infect Chemother. 2010 Feb;16(1):25-32. doi: 10.1007/s10156-009-0022-3.

PMID:
20082106
4.

Pharmacokinetic-pharmacodynamic target attainment analysis of cefozopran in Japanese adult patients.

Ikawa K, Nomura K, Morikawa N, Ikeda K, Ohge H, Sueda T, Taniwaki M.

J Infect Chemother. 2008 Apr;14(2):130-6. doi: 10.1007/s10156-008-0589-0.

PMID:
18622676
5.

Population pharmacokinetics of imipenem in critically ill patients with suspected ventilator-associated pneumonia and evaluation of dosage regimens.

Couffignal C, Pajot O, Laouénan C, Burdet C, Foucrier A, Wolff M, Armand-Lefevre L, Mentré F, Massias L.

Br J Clin Pharmacol. 2014 Nov;78(5):1022-34. doi: 10.1111/bcp.12435.

6.

Population pharmacokinetic and pharmacodynamic modeling of high-dose intermittent ticarcillin-clavulanate administration in pediatric cystic fibrosis patients.

Zobell JT, Stockmann C, Young DC, Cash J, McDowell BJ, Korgenski K, Sherwin CM, Spigarelli M, Chatfield BA, Ampofo K.

Clin Ther. 2011 Nov;33(11):1844-50. doi: 10.1016/j.clinthera.2011.09.010.

PMID:
22018680
7.

Population pharmacokinetics and pharmacodynamics of meropenem in Japanese pediatric patients.

Ikawa K, Morikawa N, Ikeda K, Miki M, Kobayashi M.

J Infect Chemother. 2010 Apr;16(2):139-43. doi: 10.1007/s10156-009-0025-0.

PMID:
20094749
8.

Pharmacokinetic-pharmacodynamic target attainment analysis of doripenem in infected patients.

Ikawa K, Morikawa N, Uehara S, Monden K, Yamada Y, Honda N, Kumon H.

Int J Antimicrob Agents. 2009 Mar;33(3):276-9. doi: 10.1016/j.ijantimicag.2008.08.031.

PMID:
19095418
9.

Pharmacokinetics of imipenem in critically ill patients during empirical treatment of nosocomial pneumonia: a comparison of 0.5-h and 3-h infusions.

Lipš M, Siller M, Strojil J, Urbánek K, Balík M, Suchánková H.

Int J Antimicrob Agents. 2014 Oct;44(4):358-62. doi: 10.1016/j.ijantimicag.2014.05.011.

PMID:
25216543
10.

[Clinical and pharmacokinetic study of imipenem/cilastatin in children and newborn infants].

Bégué P, Quinet B, Baron S, Challier P, Fontaine JL, Lasfargues G.

Pathol Biol (Paris). 1989 May;37(5):485-90. French.

PMID:
2674874
11.

Population pharmacokinetic-pharmacodynamic target attainment analysis of sulbactam in patients with impaired renal function: dosing considerations for Acinetobacter baumannii infections.

Yokoyama Y, Matsumoto K, Ikawa K, Watanabe E, Morikawa N, Takeda Y.

J Infect Chemother. 2015 Apr;21(4):284-9. doi: 10.1016/j.jiac.2014.12.005.

PMID:
25638291
12.

Imipenem in burn patients: pharmacokinetic profile and PK/PD target attainment.

Gomez DS, Sanches-Giraud C, Silva CV Jr, Oliveira AM, da Silva JM Jr, Gemperli R, Santos SR.

J Antibiot (Tokyo). 2015 Mar;68(3):143-7. doi: 10.1038/ja.2014.121.

PMID:
25227503
14.

Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units.

Roos JF, Bulitta J, Lipman J, Kirkpatrick CM.

J Antimicrob Chemother. 2006 Nov;58(5):987-93.

PMID:
16943209
15.

Pharmacokinetic and clinical evaluation of imipenem/cilastatin in children and neonates.

Bégué PC, Baron S, Challier P, Fontaine JL, Lasfargues G.

Scand J Infect Dis Suppl. 1987;52:40-5.

PMID:
3483288
16.

Optimal treatment schedule of meropenem for adult patients with febrile neutropenia based on pharmacokinetic-pharmacodynamic analysis.

Ohata Y, Tomita Y, Nakayama M, Tamura K, Tanigawara Y.

J Infect Chemother. 2011 Dec;17(6):831-41. doi: 10.1007/s10156-011-0271-9.

PMID:
21773752
17.

Vancomycin dosing assessment in intensive care unit patients based on a population pharmacokinetic/pharmacodynamic simulation.

Revilla N, Martín-Suárez A, Pérez MP, González FM, Fernández de Gatta Mdel M.

Br J Clin Pharmacol. 2010 Aug;70(2):201-12. doi: 10.1111/j.1365-2125.2010.03679.x.

18.
19.

Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation.

Lee LS, Kinzig-Schippers M, Nafziger AN, Ma L, Sörgel F, Jones RN, Drusano GL, Bertino JS Jr.

Diagn Microbiol Infect Dis. 2010 Nov;68(3):251-8. doi: 10.1016/j.diagmicrobio.2010.06.012.

PMID:
20851549
20.

Optimal dosage regimen of meropenem for pediatric patients based on pharmacokinetic/pharmacodynamic considerations.

Ohata Y, Tomita Y, Nakayama M, Kozuki T, Sunakawa K, Tanigawara Y.

Drug Metab Pharmacokinet. 2011;26(5):523-31.

Supplemental Content

Support Center